Clin Mol Hepatol.
2024 Jul;30(3):582-584. 10.3350/cmh.2023.0555.
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Affiliations
-
- 1Wuxi Medical Center, Nanjing Medical University, Jiangsu, China
- 2Wuxi Maternal and Child Health Hospital,Wuxi School of Medicine, Jiangnan University, Jiangsu, China
- 3Department of Laboratory, Haidong Second People’s Hospital, Haidong, China
- KMID: 2557404
- DOI: http://doi.org/10.3350/cmh.2023.0555
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- Waiting for the changes after the adoption of steatotic liver disease
- Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
